Kaplan University nursing alum Debra Eppley was already working in the nursing field when she started her RN-to-Bachelor of Science in Nursing completion program (RN-to-BSN program). Kaplan University’s flexibility and support offered her the opportunity to complete her degree online while continuing to work. Once she completed her Bachelor of Science Nursing online, she was able to make a career move that not only increased her salary, but also her level of job satisfaction.
Kaplan University makes taking online nursing classes a streamlined process. Every day nurses choose Kaplan University for their online master’s degree programs. The distance learning curriculum makes a nursing degree obtainable for working professionals. Nursing as a career is a rewarding occupation that could allow for a wide range of employment opportunities beyond the hospital doors.* The Kaplan University School of Nursing offers online nursing degrees such as an the RN-to- BSN completion program, the RN-to-MSN option, and nurse practitioner certificate programs† to help get you where you want to be. Nursing programs at Kaplan University, including the MSN programs online, are designed for nurses that are already in the field. It’s this unique approach that sets Kaplan University apart.
*Kaplan University's programs are designed to prepare graduates to pursue employment in their field of study, or in related fields. However, the University does not guarantee that graduates will be placed in any particular job, eligible for job advancement opportunities, or employed at all. Additional training or certification may be required.
† At this time, the nurse practitioner certificates are available only in the following states: California, Connecticut, Delaware, Florida, Iowa, Michigan, Mississippi, Montana, Oklahoma, Rhode Island, South Carolina, South Dakota, and Vermont.
“I got out of high school and started working. I had a family very young. About the time I was 28 I decided I needed to go to school. I went and got my associate’s degree in nursing at that time. I had worked in labor and delivery, and that’s my niche. I like it–I like babies, I like seeing families with their babies. Then I thought, I love floor nursing but there was something else I wanted to do.
We are in Coshocton, Ohio, which is very near to the heart of Amish country. I just needed to step out and do something else for myself. What I thought I would like to do required a bachelor’s degree and so I started looking down that road. I had kind of shopped around on the net looking for every last online class. You’re looking at price, you’re looking at length, you’re looking at what kind of clinical requirements are there–especially for me in nursing. I just started weeding and narrowing it down and I kept coming back to Kaplan University because it seemed to fit what I wanted to do at that time.
I enrolled to start my bachelor’s degree. There were times when I thought I was going to quit–family life is too much, work is too much, school is too much. I thought, no wasn’t an option. But of course that thought of having that extra two year degree bumps that salary up immensely. I was also thinking, ‘I’m going to have four kids I have to put through college, because now I’m encouraging them to go to college so I need to find a way to help them pay for that, too.
Financially going back to school was a huge plus. This January the head of OB at the time decided to leave her position, and it was open. They posted the job and I debated long and hard because I thought, ‘It’s too soon,’ ‘I can’t be there yet,’ and after much coaxing from a few of my coworkers, my husband, and my mother, I went ahead and I applied for the job and they hired me.
I started the end of March; I am now the OB coordinator, so I manage the whole OB department. It’s just a huge feeling of pride. My Kaplan [University] experience was fantastic. They just want to see you succeed and they want to help you get there. You have a job, you have a
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/pvct/43978/
In their ongoing commitment to support fearless women, Secret Deodorant has created the Mean Stinks program; a supportive Facebook community that gives young women the courage to stand up to a stinky behavior – bullying. To help this cause, Secret is partnering with relatable role models—Amber Riley, best known as Mercedes on the hit FOX show Glee, and Rachel Simmons, nationally renowned relationship expert—to start a movement of “nice.” Together they are giving young women the strength to face challenges associated with bullying and mean behavior. Secret is also partnering with PACER’s National Bullying Prevention Center by donating a portion of proceeds from select Secret Clinical Strength purchases to it’s prevention efforts.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/meanstinks/50863/
Boston Scientific Corporation (NYSE: BSX) announces positive clinical data from the Research in Severe Asthma (RISA) Trial, demonstrating the long-term safety of bronchial thermoplasty (BT) in patients treated with the Company’s AlairTM Bronchial Thermoplasty System. Follow-up data demonstrate that stable lung function is maintained and late clinical complications are absent over a five-year period in patients with severe refractory asthma treated with BT. Results were presented today at the annual European Respiratory Society (ERS) Congress in Amsterdam by Michel Laviolette, M.D., Professor of Medicine, Institut universitaire de cardiologie et de pneumologie at Université Laval in Québec City, Canada.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/bostonscientific/52128/
CVS/pharmacy has kicked-off its ninth annual in-store fund raising campaign to support the fight against amyotrophic lateral sclerosis (ALS). Since 2002, CVS/pharmacy has partnered with the ALS Therapy Alliance (ATA) to help advance ALS research. To date, CVS/pharmacy has raised more than $19 million in its stores—a single $1 donation at a time—to support the funding of new clinical research with the aim of discovering a treatment or cure for this devastating disease. This year's campaign began on June 6 and runs through June 26.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/44466/
University Hospitals (UH) Case Medical Center has announced a $250 million initiative that promises to dramatically change how drugs will advance from discovery in the laboratories to commercialization, resulting in greater access to advanced treatments and cures for patients. The first-of-its-kind initiative, named The Harrington Project for Discovery & Development, is powered by a $50 million gift – the largest donation in the health system’s history – from the Harrington family, recognized entrepreneurs and philanthropists in Cleveland.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54909-university-hospitals-uh-harrington-discovery-institute-development-project
Nestlé Health Science will unveil its pediatric closed system formulas with the new SpikeRight® PLUS port at the annual American Society for Parenteral and Enteral Nutrition’s (A.S.P.E.N.) Clinical Nutrition Week meeting being held in Orlando January 21-24. The introduction marks a significant step in supporting the provision of safe enteral (tube) feeding.
Enteral tubing misconnections, where feeding solutions are wrongly administered through intravenous (IV) tubing or other non-enteral systems, have been a concern for nearly thirty years. Most commonly occurring in intensive care settings, where patients have multiple types of tubing connections, an enteral tubing misconnection can result in catastrophic complications and possibly death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53580-nestle-health-science-launches-next-generation-spikeright-plus-pediatrics
Ortho Clinical Diagnostics (OCD), in partnership with the National Association of Chronic Disease Directors (NACDD), today unveiled new consumer survey results and a report revealing the state of blood test health literacy in the United States with strategies to support much-needed patient education and empowerment. The first step: ensuring patient access to and understanding of blood test results, a critical component to maintaining health and wellness. The campaign kicks off during National Health Literacy Month, an awareness effort founded in 1999 to promote the importance of understandable health information.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52662-ortho-clinical-diagnostics-and-nacdd-blood-test-health-literacy-survey
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave.
Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy
Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world’s largest stem cell bank, are launching the first FDA- approved clinical trial to assess the use of a child’s own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57707-cord-blood-registry-stem-cell-trials-child-autism
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor™ System for rapid detection of Flu A+B. This is the first rapid influenza test system that incorporates a digital read out of results to receive CLIA waiver.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53615-bd-veritor-system-influenza-test-receives-510k-clearance-fda-clia-waiver
